Novo and Lilly Show GLP-1 Drugs May Add Years and Slow Biological Aging
Early data from ARDD 2026 suggest semaglutide and tirzepatide reduce biological age estimates and project meaningful life-year gains.
Summary
At the 2026 Aging Research and Drug Discovery conference at Harvard, Novo and Eli Lilly presented early evidence that GLP-1 drugs may extend healthy lifespan. Novo modeled 1.9 additional life-years from semaglutide use in a UK cohort of over 19,000 people, with larger gains at younger treatment ages. Semaglutide also lowered proteomic biological age within 13–20 weeks in cardiovascular trials. Lilly shared epigenetic data from a SURMOUNT-5 sub-study showing tirzepatide slowed biological aging across 15 epigenetic clocks, with two reaching statistical significance. Pace-of-aging measures like DunedinPACE also improved. Both companies heavily caveated the findings as early-stage, but the consistency across independent labs and multiple clock types is promising for longevity medicine.
Detailed Summary
GLP-1 receptor agonists — already transforming obesity and diabetes treatment — are now generating serious early evidence as longevity drugs. At ARDD 2026, held at Harvard, both Novo and Eli Lilly stepped beyond speculation and presented data, marking a meaningful shift from pharma interest to pharma measurement in the aging field.
Novo's Global R&D Project Leader Nikolaj K Roed presented modeled projections from the SELECT trial applied to a UK real-world semaglutide cohort of 19,117 patients. The model estimated 1.9 additional life-years on average, with the largest gains accruing to those who started treatment younger. Separately, proteomic biological age estimates across cardiovascular outcome trials showed semaglutide lowering biological age within just 13–20 weeks, with effects sustained or enhanced over 150 weeks. Proteomic signatures also pointed to improvements in vitality and locomotion — functional healthspan markers, not just mortality statistics.
Lilly's VP of Aging Research Kevin Duffin presented an epigenetic sub-study embedded within SURMOUNT-5, the head-to-head trial of tirzepatide versus semaglutide. Paired whole-blood samples from 71 participants at baseline and week 72 were analyzed independently by Zymo Research and TruDiagnostic. All 15 epigenetic clocks tested showed less aging than the 1.38 chronological years elapsed; two reached statistical significance with median gains of 1.1 and 0.7 years. The DunedinPACE pace-of-aging clock fell from a median of 1.13 to 1.08 in the Zymo dataset, a direction independently confirmed by TruDiagnostic across six second-generation clocks including GrimAge V1 and V2.
Organ-specific clocks suggested lower predicted age in the immune system, kidneys, liver, and cardiovascular tissue — aligning with the improved clinical outcomes seen in patient trials and lending biological plausibility to the life-year projections.
Both presentations were explicitly framed as early, hypothesis-generating work. Sample sizes are small, modeling assumptions matter, and epigenetic clocks remain debated as aging biomarkers. Larger, prospective longevity trials are needed before these findings translate to practice. Nevertheless, the convergence of proteomic, epigenetic, and mortality data across two independent drug programs is the most substantive pharmaceutical signal in longevity medicine to date.
Key Findings
- Semaglutide modeled to add 1.9 life-years in a 19,117-person UK cohort, with greatest gains at younger treatment ages.
- Semaglutide lowered proteomic biological age within 13–20 weeks across cardiovascular trials, effects sustained over 150 weeks.
- Tirzepatide slowed biological aging across all 15 epigenetic clocks tested in a 72-week sub-study; two reached statistical significance.
- DunedinPACE pace-of-aging score dropped from 1.13 to 1.08 with tirzepatide; confirmed by two independent labs.
- Organ clocks showed lower predicted age in immune, kidney, liver, and cardiovascular tissue, matching clinical trial outcomes.
Methodology
This is a news report from Longevity.Technology summarizing live conference presentations at ARDD 2026, not a peer-reviewed publication. Novo's data are modeled projections from the SELECT trial applied to a real-world cohort; Lilly's data are from a small epigenetic sub-study (82 subjects, 71 paired) within SURMOUNT-5. Independent lab replication (Zymo and TruDiagnostic) strengthens internal consistency but primary data have not yet been published or peer-reviewed.
Study Limitations
All findings are early-stage and heavily caveated by the presenting companies themselves. Lilly's epigenetic sub-study included only 82 subjects and has not been peer-reviewed. Novo's life-year projections are model-derived, not observed outcomes. Epigenetic clocks are still debated biomarkers; clock improvements do not yet guarantee actual lifespan extension.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: